Good
Partially Aligned
Patient Risk:
Low
Summary
Two claims about FDA approval timing are not supported or verifiable from the provided FDA label text (only Indications/Dosage/Warnings excerpts). The third claim about lack of EU/UK launch dates is consistent with the provided information and is not contradicted.
Category Scores
Accurate Statements
The provided information supports US approval timing (May 2017) but does not provide country-by-country launch dates for EU/UK/other markets.
Not contradicted by the provided label excerpts; however, EU/UK launch dates are not addressed in the supplied label text, so support is limited to absence of information rather than explicit label confirmation.
Unsupported Statements
Imfinzi (durvalumab) was approved by the FDA in May 2017 for non–small cell lung cancer (NSCLC).
The supplied prescribing information excerpts do not include FDA approval date or initial approval timeline; therefore the May 2017 approval timing and the specific linkage to NSCLC cannot be verified from the provided label text.
Durvalumab (Imfinzi) received its initial FDA approval in May 2017 for a specific NSCLC indication.
The supplied prescribing information excerpts do not provide initial approval date (May 2017) or initial NSCLC indication timing; cannot be confirmed from the provided label text.
Contradictions
Important Omissions
The response asserts FDA approval timing (May 2017) and initial approval indication, but the provided label excerpts do not contain this information; the response should not treat label excerpts as evidence for approval dates.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims concern historical approval timing and do not affect dosing, contraindications, warnings, or administration as presented in the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
FDA approval timing (May 2017) and initial approval indication are not supported/verifiable from the provided prescribing information excerpts.
Suggested Improvement
Remove or qualify approval-date statements unless the exact label section (e.g., History of Revisions/approval information) is provided that explicitly supports May 2017 and the initial indication.